14 million Americans suffer migraine headaches every day. Many go untreated and many who are treated continue to have headaches. But an old drug proved to offer a new way to treat migraines, with the FDA approval of botulinum toxin injections for severe chronic migraine. Dr. David Simpson, professor of neurology at Mount Sinai School of Medicine in New York City and director of the clinical neurophysiology lab at Mount Sinai Hospital, joins host Dr. Anthony Alessi to discuss what patients qualify for this treatment, problems and risks associated with taking the injections, and the controversial results of the earlier clinical trials for this treatment.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Repurposing Botulinum Toxin as Treatment for Chronic Migraines
Restart
Resume
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
14 million Americans suffer migraine headaches every day. Many go untreated and many who are treated continue to have headaches. But an old drug proved to offer a new way to treat migraines, with the FDA approval of botulinum toxin injections for severe chronic migraine. Dr. David Simpson, professor of neurology at Mount Sinai School of Medicine in New York City and director of the clinical neurophysiology lab at Mount Sinai Hospital, joins host Dr. Anthony Alessi to discuss what patients qualify for this treatment, problems and risks associated with taking the injections, and the controversial results of the earlier clinical trials for this treatment.
Presenters
Facebook Comments